Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2015

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

Bortezomib, Rituximab, Dexamethasone

"Bortezomib as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1.~On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each 35-day cycle.~Dexamethasone IV 40 mg will be given on cycles 2 and 5 on days 1,8,15,22 Rituximab IV will be given on cycles 2 and 5, 375 mg/m2, on days 1,8,15,22 iv"

Trial Locations (4)

11528

Laikon Hospital, Athens

37007

Hospital Universitario de Salamanca, Salamanca

115 28

Alexandra Hospital , Department of Clinical Therapeutics, Athens

3015 CE

Erasmus Medical Center, Rotterdam

All Listed Sponsors
collaborator

European Myeloma Network B.V.

NETWORK

lead

Meletios A. Dimopoulos

OTHER

NCT01046006 - Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia | Biotech Hunter | Biotech Hunter